Skip to Content

Helix BioPharma Corp HBPCF

Morningstar Rating
$0.14 0.00 (2.55%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

HBPCF is trading within a range we consider fairly valued.
Price
$0.14
Fair Value
$9.93
Uncertainty
Extreme
1-Star Price
$6.59
5-Star Price
$3.29
Economic Moat
Qwvznl
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if HBPCF is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.15
Day Range
$0.140.14
52-Week Range
$0.140.15
Bid/Ask
$0.22 / $0.74
Market Cap
$30.62 Mil
Volume/Avg
900 / 6,475

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidates are Tumor Defence Breaker L-DOS47, and, V-DOS47 among others.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
7

Valuation

Metric
HBPCF
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
HBPCF
Quick Ratio
1.34
Current Ratio
1.46
Interest Coverage
−459.08
Quick Ratio
HBPCF

Profitability

Metric
HBPCF
Return on Assets (Normalized)
−214.33%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
−1,316.83%
Return on Assets
HBPCF
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRPqjf$531.9 Bil
VRTX
Vertex Pharmaceuticals IncYyhbp$108.7 Bil
REGN
Regeneron Pharmaceuticals IncFpddymw$106.0 Bil
MRNA
Moderna IncJpss$35.2 Bil
ARGX
argenx SE ADRPrcs$22.1 Bil
BNTX
BioNTech SE ADRXsfs$21.1 Bil
ALNY
Alnylam Pharmaceuticals IncSpkjmg$19.0 Bil
BMRN
Biomarin Pharmaceutical IncYggkms$16.3 Bil
RPRX
Royalty Pharma PLC Class ARftjf$13.6 Bil
INCY
Incyte CorpTpttwnp$13.1 Bil

Sponsor Center